Clinical trial
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
NCT00181558 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00181558 |
|---|---|
| Title | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone |
| Official title | Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Brigham and Women's Hospital Abbott Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Adenocarcinoma of the Prostate |
| Intervention type | Drug |
| Interventions | Atrasentan, Zoledronic Acid (Zometa) |
| Enrollment | 44 |
| Start date | Dec 1, 2001 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | May 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: